Peter Hulick to Risk Assessment
This is a "connection" page, showing publications Peter Hulick has written about Risk Assessment.
Connection Strength
0.376
-
Multicenter development and validation of a risk stratification tool for ward patients. Am J Respir Crit Care Med. 2014 Sep 15; 190(6):649-55.
Score: 0.146
-
Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers. J Natl Cancer Inst. 2017 07 01; 109(7).
Score: 0.044
-
Association of Reported Candidate Monogenic Genes With Lung Cancer Risk. Clin Lung Cancer. 2023 06; 24(4):313-321.
Score: 0.033
-
Inherited risk assessment and its clinical utility for predicting prostate cancer from diagnostic prostate biopsies. Prostate Cancer Prostatic Dis. 2022 09; 25(3):422-430.
Score: 0.031
-
Observed evidence for guideline-recommended genes in predicting prostate cancer risk from a large population-based cohort. Prostate. 2021 09; 81(13):1002-1008.
Score: 0.029
-
Calibration of polygenic risk scores is required prior to clinical implementation: results of three common cancers in UKB. J Med Genet. 2022 03; 59(3):243-247.
Score: 0.028
-
Transcriptome-wide association study of breast cancer risk by estrogen-receptor status. Genet Epidemiol. 2020 07; 44(5):442-468.
Score: 0.027
-
BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers. J Natl Cancer Inst. 2016 Feb; 108(2).
Score: 0.020
-
Variable clinical presentation of an MUC1 mutation causing medullary cystic kidney disease type 1. Clin J Am Soc Nephrol. 2014 Mar; 9(3):527-35.
Score: 0.018